Physician profile
Charles Tuan-Tu S Nguyen
NPI 1942380118
$2,136,610.74
in general payments reported to CMS, 2019-2025
24 companies · $580K in 2025
The $580K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $77K · 2021: $105K · 2022: $261K · 2023: $430K · 2024: $514K · 2025: $580K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Consulting Fee: $178K · Travel and Lodging: $144K · Honoraria: $101K · Food and Beverage: $41K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,060,292.14 |
| Consulting Fee | $177,762.00 |
| Travel and Lodging | $143,931.26 |
| Honoraria | $101,108.50 |
| Food and Beverage | $41,455.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $957,371.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $536,864.71 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $356,712.67 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $219,034.69 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $59,067.12 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $1,760.57 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,570.60 | 2019-2025 | Rexulti, Abilify Asimtufii, Rejoyn |
| Alkermes, INC. | $1,279.41 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $699.86 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Allergan, INC. | $408.51 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $405.55 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $349.18 | 2021-2025 | |
| Indivior INC. | $233.63 | 2022-2024 | Perseris |
| Lundbeck LLC | $216.00 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $186.02 | 2022-2023 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $125.00 | 2023 | Igalmi |
| Idorsia Pharmaceuticals US INC | $123.32 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $55.17 | 2020-2022 | |
| Biogen, INC. | $47.24 | 2023 | |
| Noven Pharmaceuticals, INC. | $38.80 | 2020 | |
| Luye Pharma (USA) Ltd. | $17.78 | 2025 | Erzofri Extended-Release |
| Eisai INC. | $17.46 | 2021 | |
| Tris Pharma INC | $13.86 | 2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Tuan-Tu Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.